Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
This Study is
No Longer Enrolling
Adult
Phase II is restricted to NSCLC, head and neck squamous cell cancer, gastric or gastroesophageal carcinoma, hepatocellular carcinoma and nasopharyngeal carcinoma
I/II - A combination of phases: (1) Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants; and (2) Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Treatment
University of Colorado Hospital
Protocol Number: 18-1263
More information available at ClinicalTrials.gov: NCT03744468
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers